Kirk Tiemann, MD
Family Medicine · Lubbock, TXNPI 1427249564
Payments from drug & device makers
Across 213 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$604
- Exeltis, USA Inc.$311
- Amgen$244
- Biohaven Pharmaceuticals, Inc.$143
- AbbVie$104
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,888100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $1,294 |
| GSK | 38 | $604 |
| Exeltis, USA Inc. | 2 | $311 |
| Amgen(2 entities) | 14 | $244 |
| Biohaven Pharmaceuticals, Inc. | 11 | $143 |
| AbbVie(2 entities) | 6 | $104 |
| Lilly USA, LLC | 6 | $99 |
| Johnson & Johnson(2 entities) | 3 | $77 |
| Boehringer Ingelheim | 3 | $74 |
| Amarin Pharma, Inc. | 5 | $71 |
| Dynasplint Systems Inc. | 1 | $69 |
| Eisai Inc. | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Novo Nordisk | 4 | $59 |
| Arbor Pharmaceuticals, Inc. | 3 | $58 |
| Genentech USA, Inc. | 3 | $56 |
| Verona Pharma, Inc. | 2 | $45 |
| Dexcom, Inc. | 2 | $42 |
| Exact Sciences | 2 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| Bayer | 2 | $37 |
| Lundbeck LLC | 1 | $27 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Merck | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Organogenesis Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Pacira Therapeutics, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Optos, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Lupin Inc. | 1 | $12 |
| Apria Healthcare LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Slynd$270
How this compares
$3,888 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 15 | $24,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $23,130 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $18,186 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $15,156 |
| FarxigaDapagliflozin Propanediol | 15 | $12,003 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,484 |
| LinzessLinaclotide | 13 | $6,752 |
| Icosapent Ethyl | 25 | $6,106 |
| PaxlovidNirmatrelvir/Ritonavir | 36 | $2,858 |
| Levothyroxine Sodium | 261 | $2,280 |
| Eszopiclone | 17 | $1,774 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,414 |
| Diclofenac Sodium | 13 | $1,284 |
| Finasteride | 90 | $1,242 |
| Lisinopril | 155 | $1,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,294 | $39,67481 claims |
| Lilly USA, LLCMounjaro | $99 | $24,28915 claims |
| GSKTrelegy Ellipta | $604 | $23,13037 claims |
| MerckJanumet | $25 | $15,15620 claims |
| AbbVieLinzess, Synthroid | $104 | $7,79137 claims |
| PfizerPaxlovid | $14 | $2,85836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lubbock
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.